Swedish Orphan Biovitrum AB’s (publ) (Sobi™) Chairman of the Board, Bo Jesper Hansen,MD, PhD, has informed the Sobi’s nomination committee that he will not stand for re-election at the 2016 annual general meeting of shareholders (AGM). Bo Jesper Hansen has been Chairman of the Board since the merger of Biovitrum and Swedish Orphan International in 2010. During his tenure, Sobi has grown to become an international pioneer in rare diseases with a strong commercial footprint across Europe, North America, the Middle East and Russia.
The Nomination Committee will propose that the shareholders elect Håkan Björklund, PhD, as the new Chairman of the Board for Sobi. Håkan Björklund is the former CEO of Nycomed and currently serves as Industry Executive at Avista Capital Partners.He has served as a Member of the Board of Directors of several international life science companies including Alere, Coloplast, Danisco, and Lundbeck. Between 2001 and 2007, Håkan Björklund also served as member of the Board of Directors for Biovitrum.
The nomination committee’s work will continue and the rest of the committee’s proposals will be announced at a later date in connection with the notice of the 2016 Annual General Meeting.
Sobi is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primary focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
Oskar Bosson, Head of Communications
T: +46 70 410 71 80
Jörgen Winroth, Vice President, Head of Investor Relations
T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135